Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Telmisartan + amlodipine + hydrochlorothiazide** is an oral fixed-dose triple antihypertensive combination used for hypertension. It combines telmisartan, an angiotensin II type 1 receptor blocker; amlodipine, a dihydropyridine L-type calcium-channel blocker; and hydrochlorothiazide, a thiazide diuretic that inhibits renal sodium-chloride reabsorption. The complementary mechanisms lower blood pressure by reducing angiotensin II-mediated vasoconstriction and aldosterone signaling, relaxing arterial smooth muscle, and promoting natriuresis. In Japan, the 80 mg/5 mg/12.5 mg tablet has been marketed by Boehringer Ingelheim as Micatrio. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/65/NCT03021265/Prot_000.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on telmisartan + amlodipine + hydrochlorothiazide.